180 related articles for article (PubMed ID: 36701932)
1. Fenfluramine treatment for Dravet syndrome: Caregiver- and clinician-reported benefits on the quality of life of patients, caregivers, and families living in Germany, Spain, Italy, and the United Kingdom.
Jensen MP; Gammaitoni AR; Salem R; Wilkie D; Lothe A; Amtmann D
Epilepsy Res; 2023 Feb; 190():107091. PubMed ID: 36701932
[TBL] [Abstract][Full Text] [Related]
2. Fenfluramine treatment for dravet syndrome: Real-world benefits on quality of life from the caregiver perspective.
Jensen MP; Gammaitoni AR; Galer BS; Salem R; Wilkie D; Amtmann D
Epilepsy Res; 2022 Sep; 185():106976. PubMed ID: 35843016
[TBL] [Abstract][Full Text] [Related]
3. Improved everyday executive functioning following profound reduction in seizure frequency with fenfluramine: Analysis from a phase 3 long-term extension study in children/young adults with Dravet syndrome.
Bishop KI; Isquith PK; Gioia GA; Gammaitoni AR; Farfel G; Galer BS; Nabbout R; Wirrell EC; Polster T; Sullivan J
Epilepsy Behav; 2021 Aug; 121(Pt A):108024. PubMed ID: 34023810
[TBL] [Abstract][Full Text] [Related]
4. Caregiver-reported outcomes with real-world use of cannabidiol in Lennox-Gastaut syndrome and Dravet syndrome from the BECOME survey.
Berg AT; Dixon-Salazar T; Meskis MA; Danese SR; Le NMD; Perry MS
Epilepsy Res; 2024 Feb; 200():107280. PubMed ID: 38183688
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, tolerability, and retention of fenfluramine for the treatment of seizures in patients with Dravet syndrome: Compassionate use program in Germany.
Strzelczyk A; Pringsheim M; Mayer T; Polster T; Klotz KA; Muhle H; Alber M; Trollmann R; Spors H; Kluger G; Kurlemann G; Schubert-Bast S
Epilepsia; 2021 Oct; 62(10):2518-2527. PubMed ID: 34378197
[TBL] [Abstract][Full Text] [Related]
6. Patient and Caregiver Health State Utilities in Lennox-Gastaut Syndrome and Dravet Syndrome.
Lo SH; Lloyd A; Marshall J; Vyas K
Clin Ther; 2021 Nov; 43(11):1861-1876.e16. PubMed ID: 34774333
[TBL] [Abstract][Full Text] [Related]
7. Fenfluramine significantly reduces day-to-day seizure burden by increasing number of seizure-free days and time between seizures in patients with Dravet syndrome: A time-to-event analysis.
Sullivan J; Specchio N; Devinsky O; Auvin S; Perry MS; Strzelczyk A; Gil-Nagel A; Dai D; Galer BS; Gammaitoni AR
Epilepsia; 2022 Jan; 63(1):130-138. PubMed ID: 34676542
[TBL] [Abstract][Full Text] [Related]
8. Fenfluramine treatment is associated with improvement in everyday executive function in preschool-aged children (<5 years) with Dravet syndrome: A critical period for early neurodevelopment.
Bishop KI; Isquith PK; Gioia GA; Knupp KG; Scheffer IE; Nabbout R; Specchio N; Sullivan J; Auvin S; Helen Cross J; Guerrini R; Farfel G; Galer BS; Gammaitoni AR
Epilepsy Behav; 2023 Jan; 138():108994. PubMed ID: 36463826
[TBL] [Abstract][Full Text] [Related]
9. Perception of impact of Dravet syndrome on children and caregivers in multiple countries: looking beyond seizures.
Nabbout R; Auvin S; Chiron C; Thiele E; Cross H; Scheffer IE; Schneider AL; Guerrini R; Williamson N;
Dev Med Child Neurol; 2019 Oct; 61(10):1229-1236. PubMed ID: 30828793
[TBL] [Abstract][Full Text] [Related]
10. Caregiver impact and health service use in high and low severity Dravet syndrome: A multinational cohort study.
Lagae L; Irwin J; Gibson E; Battersby A
Seizure; 2019 Feb; 65():72-79. PubMed ID: 30616222
[TBL] [Abstract][Full Text] [Related]
11. What have we learned from the real-world efficacy of FFA in DS and LGS? A post-marketing study in clinical practice.
Valls Carbó A; Beltrán Á; Sánchez-Miranda Román I; Cabal B; Gómez-Porro P; Aledo-Serrano Á; López Sobrino G; Ayuga F; Gómez Eguilaz M; Gil-Nagel A
Epilepsy Behav; 2024 Feb; 151():109620. PubMed ID: 38194770
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: A real-world study.
Specchio N; Pietrafusa N; Doccini V; Trivisano M; Darra F; Ragona F; Cossu A; Spolverato S; Battaglia D; Quintiliani M; Luigia Gambardella M; Rosati A; Mei D; Granata T; Dalla Bernardina B; Vigevano F; Guerrini R
Epilepsia; 2020 Nov; 61(11):2405-2414. PubMed ID: 32945537
[TBL] [Abstract][Full Text] [Related]
13. Fenfluramine increases survival and reduces markers of neurodegeneration in a mouse model of Dravet syndrome.
Cha J; Filatov G; Smith SJ; Gammaitoni AR; Lothe A; Reeder T
Epilepsia Open; 2024 Feb; 9(1):300-313. PubMed ID: 38018342
[TBL] [Abstract][Full Text] [Related]
14. A multicenter, matched case-control analysis comparing burden-of-illness in Dravet syndrome to refractory epilepsy and seizure remission in patients and caregivers in Germany.
Strzelczyk A; Schubert-Bast S; Bast T; Bettendorf U; Fiedler B; Hamer HM; Herting A; Kalski M; Kay L; Kieslich M; Klein KM; Kluger G; Kurlemann G; Mayer T; Neubauer BA; Polster T; von Spiczak S; Stephani U; Trollmann R; Wiemer-Kruel A; Wolff M; Irwin J; Carroll J; Pritchard C; Rosenow F
Epilepsia; 2019 Aug; 60(8):1697-1710. PubMed ID: 31247127
[TBL] [Abstract][Full Text] [Related]
15. Dravet syndrome: Characteristics, comorbidities, and caregiver concerns.
Villas N; Meskis MA; Goodliffe S
Epilepsy Behav; 2017 Sep; 74():81-86. PubMed ID: 28732259
[TBL] [Abstract][Full Text] [Related]
16. Caregivers' Perspectives on the Impact of Cannabidiol (CBD) Treatment for Dravet and Lennox-Gastaut Syndromes: A Multinational Qualitative Study.
Marshall J; Skrobanski H; Moore-Ramdin L; Kornalska K; Swinburn P; Bowditch S
J Child Neurol; 2023 May; 38(6-7):394-406. PubMed ID: 37455396
[TBL] [Abstract][Full Text] [Related]
17. The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.
Gil-Nagel A; Falip M; Sánchez-Carpintero R; Abad-Sazatornil MR; Poveda JL; Aibar JÁ; Cardenal-Muñoz E; Aras LM; Sánchez R; Sancho-López A; Trillo-Mata JL; Torrejón M; Gil A
Epilepsy Behav; 2022 Jul; 132():108711. PubMed ID: 35588562
[TBL] [Abstract][Full Text] [Related]
18. The impact of seizure frequency on quality of life in patients with Lennox-Gastaut syndrome or Dravet syndrome.
Auvin S; Damera V; Martin M; Holland R; Simontacchi K; Saich A
Epilepsy Behav; 2021 Oct; 123():108239. PubMed ID: 34375802
[TBL] [Abstract][Full Text] [Related]
19. Sleep quality, anxiety, symptoms of depression, and caregiver burden among those caring for patients with Dravet syndrome: a prospective multicenter study in Germany.
Maltseva M; Schubert-Bast S; Zöllner JP; Bast T; Mayer T; von Spiczak S; Ruf S; Trollmann R; Wolff M; Hornemann F; Klotz KA; Jacobs J; Kurlemann G; Neubauer BA; Polster T; Syrbe S; Bertsche A; Bettendorf U; Kluger G; Flege S; Rosenow F; Kay L; Strzelczyk A
Orphanet J Rare Dis; 2023 Apr; 18(1):98. PubMed ID: 37120555
[TBL] [Abstract][Full Text] [Related]
20. Development and content validation of a preliminary core set of patient- and caregiver-relevant outcomes for inclusion in a potential composite endpoint for Dravet Syndrome.
Nabbout R; Auvin S; Chiron C; Irwin J; Mistry A; Bonner N; Williamson N; Bennett B
Epilepsy Behav; 2018 Jan; 78():232-242. PubMed ID: 29108913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
